| For: | Singh AK, Singh R. Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. World J Cardiol 2022; 14(6): 329-342 [PMID: 35979179 DOI: 10.4330/wjc.v14.i6.329] |
|---|---|
| URL: | https://www.wjgnet.com/1949-8462/full/v14/i6/329.htm |
| Number | Citing Articles |
| 1 |
Li-Nong JI, Yun-Dai CHEN. Consensus on glycemic management for patients with coronary heart disease and type 2 diabetes. Journal of Geriatric Cardiology 2024; 21(7) doi: 10.26599/1671-5411.2024.07.007
|
| 2 |
Takaya Matsushita, Yukihiro Wada, Masuo Saburi, Kazuo Kobayashi, Shunichiro Tsukamoto, Daiji Kawanami, Daisuke Suzuki, Daisuke Tsuriya, Hiromichi Wakui, Keizo Kanasaki, Yoshimi Muta, Kouichi Tamura, Yasuo Takeuchi, Masao Toyoda. Influence of combination therapy with SGLT2 inhibitors and GLP-1 receptor agonists on the management of blood pressure in Japanese patients with diabetes. Hypertension Research 2026; 49(8) doi: 10.1038/s41440-026-02695-5
|
| 3 |
Ebaa Al Ozairi, Etab Taghadom, Mohammad Irshad, Anas Al Yousef, Jumana AlKandari, Werd Al-Najim, Shahd Alabdulkader, Alexander D Miras, Carel W. le Roux. Combining glucagon-like peptide 1 analogues with sodium-glucose cotransporter 2 inhibitors to treat patients with type 1 diabetes, BMI > 25 kg/m2, and chronic kidney disease – A randomised, controlled pilot study. Diabetes Research and Clinical Practice 2026; 231 doi: 10.1016/j.diabres.2025.113066
|
| 4 |
Afshin Nazari, Mostafa Cheraghi, Faraz Souri. Pathophysiological Interplay Between Cardiovascular Diseases and Metabolic Disorders: A Review of Shared Mechanisms and Emerging Therapeutic Approaches. Epidemiology and Health System Journal 2025; 12(4) doi: 10.34172/ehsj.26451
|
| 5 |
Kevin Rafael Moreno-Ramos, Jaime Isaí Gualán-Pilamunga, Jennifer Lizbeth Toapanta-Lizano, Andrés Santiago Cisneros-Barahona. Inhibidores de SGLT2 y agonistas del receptor GLP-1 en el tratamiento de la diabetes mellitus tipo 2 en adultos.. Innova Science Journal 2026; 4(2) doi: 10.63618/omd/isj/v4/n2/252
|
| 6 |
Anastasia Nikolaidou, Ioannis Ventoulis, Georgios Karakoulidis, Vasileios Anastasiou, Stylianos Daios, Spyridon-Filippos Papadopoulos, Matthaios Didagelos, John Parissis, Theodoros Karamitsos, Kalliopi Kotsa, Antonios Ziakas, Vasileios Kamperidis. Hypoglycemic Drugs in Patients with Diabetes Mellitus and Heart Failure: A Narrative Review. Medicina 2024; 60(6) doi: 10.3390/medicina60060912
|
| 7 |
Irene Caruso, Ludovico Di Gioia, Sergio Di Molfetta, Angelo Cignarelli, Suetonia Cressida Palmer, Patrizia Natale, Giovanni F.M. Strippoli, Sebastio Perrini, Annalisa Natalicchio, Luigi Laviola, Francesco Giorgino. Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis. eClinicalMedicine 2023; 64 doi: 10.1016/j.eclinm.2023.102181
|
| 8 |
Mehmet Kanbay, Rama Al-Shiab, Ermeena Shah, Lasin Ozbek, Mustafa Guldan, Alberto Ortiz, Denis Fouque. Gut microbiota modulation in GLP-1RA and SGLT-2i therapy: clinical implications and mechanistic insights in type 2 diabetes. Clinical Kidney Journal 2025; 18(12) doi: 10.1093/ckj/sfaf351
|
| 9 |
Manuel Enrique Machado-Duque, Andrés Gaviria-Mendoza, Luis Fernando Valladales-Restrepo, Jorge Enrique Machado-Alba. Persistence of Weekly Injectable Semaglutide Use in Patients with Diabetes Mellitus and Obesity: A Retrospective Follow-Up in Colombia. Drugs - Real World Outcomes 2025; 12(4) doi: 10.1007/s40801-025-00518-6
|
| 10 |
Carlos Alejandro Arragan Lezama, Julio Joel Jaramillo Ramos, David Alejandro Armas Eguizábal, Ximena Sofía Solares Ovando, Julio Cesar Minera Villagrán, Cinthya Jhoana Males Caiza. Cardiovascular-Renal-Hepatic-Metabolic Syndrome: Interlinked Pathophysiology and Integrated Management Approach. Cureus 2025; doi: 10.7759/cureus.85813
|
| 11 |
Antonina Kedyk, Oleksandr Kutsyn. Metabolic effects of empagliflozine. Diabetes Obesity Metabolic Syndrome 2022; (5) doi: 10.57105/2415-7252-2022-5-04
|
| 12 |
Shunichiro Tsukamoto, Kazuo Kobayashi, Masao Toyoda, Atsuhito Tone, Daiji Kawanami, Daisuke Suzuki, Daisuke Tsuriya, Hideo Machimura, Hidetoshi Shimura, Hiromichi Wakui, Hiroshi Takeda, Hisashi Yokomizo, Kei Takeshita, Keiichi Chin, Keizo Kanasaki, Masaaki Miyauchi, Masuo Saburi, Miwa Morita, Miwako Yomota, Moritsugu Kimura, Nobuo Hatori, Shinichi Nakajima, Shun Ito, Takashi Murata, Takaya Matsushita, Takayuki Furuki, Takuya Hashimoto, Tomoya Umezono, Yoshimi Muta, Yuichi Takashi, Kouichi Tamura. Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium‐glucose cotransporter‐2 inhibitor and glucagon‐like peptide‐1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease. Diabetes, Obesity and Metabolism 2024; 26(8) doi: 10.1111/dom.15652
|
| 13 |
Dalia Tantawy, Maram Rabih Musa Rabih, Razan Seifeldin Ibrahim Mohamed, Malaz Omer Abdelrahman Ali, Rayan Saad Aldeen Mohammed Saad Aldeen, Ali Omer Ahmed Abdelkarim, Tawasul Greeballah Awadalkreem Mohamedzain. Cardiometabolic Benefits and Risks of Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitor and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review. Cureus 2025; doi: 10.7759/cureus.96218
|
| 14 |
Lixin Du, Jiao Qin, Dengchuan Wang, Yunhui Zhao, Ning Xu, Chaowen Wu, Jianpeng Yuan. Meta-analysis assessing the effectiveness of SGLT2i+GLP1RA combination therapy versus monotherapy on cardiovascular and cerebrovascular outcomes in diabetic patients. Frontiers in Physiology 2022; 13 doi: 10.3389/fphys.2022.1028486
|
| 15 |
Krishna S. Upadhye, Hariom Patidar, Narendra Bamnia, Narendra Yadav. HbA1c reduction strategies: An overview of pharmacological interventions. National Journal of Pharmacology and Therapeutics 2025; 3(1) doi: 10.4103/NJPT.NJPT_72_24
|
| 16 |
Husam Ghanim, Sambasiva Rao Srungavarapu, Paresh Dandona, Ajay Chaudhuri. Combination of Glucagon-like Peptide-1 Receptor Agonists and Sodium–Glucose Cotransporter Inhibitors in Type 1 Diabetes: Why, when and How? An Exploration of the Rationale and Clinical Scenarios for Combining These 2 Adjunctive Agents. Endocrinology and Metabolism Clinics of North America 2026; 55(3) doi: 10.1016/j.ecl.2026.04.009
|
| 17 |
Renu Vajjiravelu, P.S. Kirtheka, Banuppriya Palani, Santhoshkumar Jayakodi, Dharmalingam Kirubakaran. Multidimensional cardiometabolic protection with SGLT2 inhibitors and GLP-1 receptor agonists in obesity, type 2 diabetes and hypertension. Obesity Medicine 2026; 62 doi: 10.1016/j.obmed.2026.100719
|
| 18 |
Evaluating the effectiveness and safety of empagliflozin versus liraglutide in managing diabetic dyslipidemia: An observational study. Asian Journal of Medical Sciences 2024; 15(7) doi: 10.71152/ajms.v15i7.3404
|
| 19 |
André J. Scheen. GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy. Drugs 2024; 84(11) doi: 10.1007/s40265-024-02090-9
|
| 20 |
Nada Maher Mahmoud, Amal Hussein, Bashair M. Mussa, Salah Abusnana. Real-World Evidence of the GLP-1RA/SGLT2-i Therapy versus Standard Care: A Retrospective Cohort Study. Clinical Medicine Insights: Endocrinology and Diabetes 2026; 19 doi: 10.1177/11795514261471399
|
| 21 |
Aftab Ahmad, Hani Sabbour. Effectiveness and safety of the combination of sodium–glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies. Cardiovascular Diabetology 2024; 23(1) doi: 10.1186/s12933-024-02192-4
|
| 22 |
Sanket Seksaria, Bhaskar Jyoti Dutta, Mandeep Kaur, Ghanshyam Das Gupta, Surendra H. Bodakhe, Amrita Singh. Role of GLP-1 Receptor Agonist in Diabetic Cardio-renal Disorder:
Recent Updates of Clinical and Pre-clinical Evidence. Current Diabetes Reviews 2024; 20(6) doi: 10.2174/1573399820666230809152148
|
| 23 |
Vinod Kumar , V B Amulya , Manjari Sharma , B V Saikrupa . Combination Therapy of SGLT 2 Inhibitors and GLP 1 Receptor Agonists for Glycaemic Management through Weight Reduction. Journal of Drug Delivery and Therapeutics 2025; 15(1) doi: 10.22270/jddt.v15i1.6914
|
| 24 |
Jimmy Joseph. Comparative Effectiveness of SGLT2 Inhibitors and Semaglutide in Diabetic Nephropathy: A Retrospective Observational Study. Cureus 2025; doi: 10.7759/cureus.87399
|
| 25 |
Soumya Shanta Mohanty, R. R. Selvammathy, Hindustan Abdul Ahad, Edukulla Satheesh Kumar. Combined use of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for cardiovascular protection. Indian Journal of Pharmacology 2026; 58(4) doi: 10.4103/ijp.ijp_1384_25
|